Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialotetrahexosylganglioside for Bortezomib-induced Neuropathy in Multiple Myeloma
NCT02093910Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monosialotetrahexosylganglioside in peripheral neuropathy, sponsored by Sun Yat-sen University. Primary endpoint: overall incidence rate of peripheral neuropathy (PN) at 6 months. Status: unknown.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT02093910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093910.